Seer, Inc.
SEER Healthcare Biotechnology
Seer, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 23.4%, EPS grew 6.06% and free cash flow grew 36.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow SEER
Seer, Inc. (SEER) Altman Z-score
Seer, Inc.'s Altman Z-score for fiscal 2025 is −0.55, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −0.55 | (1.18) |
| FY2024 | 0.63 | (0.40) |
| FY2023 | 1.04 | (4.06) |
| FY2022 | 5.09 | (18.04) |
| FY2021 | 23.13 | (19.17) |
| FY2020 | 42.30 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.63 | — | 0.75 | |
| Retained earnings / total assets | (1.57) | — | −2.20 | |
| EBIT / total assets | (0.26) | — | −0.87 | |
| Market value of equity / total liabilities | 2.86 | — | 1.72 | |
| Sales / total assets | 0.06 | — | 0.06 | |
| Altman Z-score | Distress zone | −0.55 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 4.62 | ||
Z and Z″ put Seer, Inc. in different zones: distress zone by Z, safe zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| LENZ LENZ Therapeutics, Inc. compare | 12.0× |
| NERV Minerva Neurosciences, Inc compare | 6.0× |
| SEER Seer, Inc. | −0.5× |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | −2.4× |
| FHTX Foghorn Therapeutics Inc. compare | −4.5× |
| ARMP Armata Pharmaceuticals, Inc. compare | −10.2× |
| GNLX Genelux Corporation compare | −13.1× |
| ENGN enGene Therapeutics Inc compare | — |
| HURA TuHURA Biosciences, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets